Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oligosarcomas, IDH-mutant are distinct and aggressive.
Suwala AK, Felix M, Friedel D, Stichel D, Schrimpf D, Hinz F, Hewer E, Schweizer L, Dohmen H, Pohl U, Staszewski O, Korshunov A, Stein M, Wongsurawat T, Cheunsuacchon P, Sathornsumetee S, Koelsche C, Turner C, Le Rhun E, Mühlebner A, Schucht P, Özduman K, Ono T, Shimizu H, Prinz M, Acker T, Herold-Mende C, Kessler T, Wick W, Capper D, Wesseling P, Sahm F, von Deimling A, Hartmann C, Reuss DE. Suwala AK, et al. Among authors: sathornsumetee s. Acta Neuropathol. 2022 Feb;143(2):263-281. doi: 10.1007/s00401-021-02395-z. Epub 2021 Dec 30. Acta Neuropathol. 2022. PMID: 34967922 Free PMC article.
Exploiting nanopore sequencing for characterization and grading of IDH-mutant gliomas.
Wongsurawat T, Jenjaroenpun P, Anekwiang P, Arigul T, Thongrattana W, Jamshidi-Parsian A, Boysen G, Suriyaphol P, Suktitipat B, Srirabheebhat P, Cheunsuchon P, Tanboon J, Nookaew I, Sathornsumetee S. Wongsurawat T, et al. Among authors: sathornsumetee s. Brain Pathol. 2024 Jan;34(1):e13203. doi: 10.1111/bpa.13203. Epub 2023 Aug 13. Brain Pathol. 2024. PMID: 37574201 Free PMC article.
GLIMMERS: glioma molecular markers exploration using long-read sequencing.
Thongrattana W, Arigul T, Suktitipat B, Pithukpakorn M, Sathornsumetee S, Wongsurawat T, Jenjaroenpun P. Thongrattana W, et al. Among authors: sathornsumetee s. Bioinform Adv. 2024 Apr 15;4(1):vbae058. doi: 10.1093/bioadv/vbae058. eCollection 2024. Bioinform Adv. 2024. PMID: 38736685 Free PMC article.
Simplified approach for pathological diagnosis of diffuse gliomas in adult patients.
Santisukwongchote S, Teerapakpinyo C, Chankate P, Techavichit P, Boongird A, Sathornsumetee S, Thammachantha S, Cheunsuchon P, Tanboon J, Thorner PS, Shuangshoti S. Santisukwongchote S, et al. Among authors: sathornsumetee s. Pathol Res Pract. 2021 Jul;223:153483. doi: 10.1016/j.prp.2021.153483. Epub 2021 May 12. Pathol Res Pract. 2021. PMID: 34022681
Molecularly targeted therapy in neuro-oncology.
Sathornsumetee S, Rich JN. Sathornsumetee S, et al. Handb Clin Neurol. 2012;104:255-78. doi: 10.1016/B978-0-444-52138-5.00018-9. Handb Clin Neurol. 2012. PMID: 22230448 Review. No abstract available.
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; ACT IV trial investigators. Weller M, et al. Lancet Oncol. 2017 Oct;18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X. Epub 2017 Aug 23. Lancet Oncol. 2017. PMID: 28844499 Free article. Clinical Trial.
Designer therapies for glioblastoma multiforme.
Sathornsumetee S, Rich JN. Sathornsumetee S, et al. Ann N Y Acad Sci. 2008 Oct;1142:108-32. doi: 10.1196/annals.1444.009. Ann N Y Acad Sci. 2008. PMID: 18990124 Review.
87 results